Table 1.
Patient characteristics.
| Total group (N = 118) | |
|---|---|
| Sex, n (%) | |
| Female | 66 (56) |
| Median age (years) at UC diagnosis (IQR) | 34 (26–44) |
| Smoking status at UC diagnosis, n (%) | |
| Smoker | 25 (21) |
| Former smoker | 31 (26) |
| Never smoker | 46 (39) |
| Unknown | 16 (14) |
| Topical treatment, n (%) | |
| Topical 5-ASA | 50 (42) |
| Topical steroids | 1 (1) |
| Combination | 65 (55) |
| Unknown | 2 (2) |
| Oral treatment, n (%) | |
| Oral 5-ASA | 34 (29) |
| Oral steroids | 6 (5) |
| Combination | 42 (36) |
| Therapy-refractory patients, n (%) | 36 (31) |
| Azathioprine, n (%) | 22 (19) |
| Median duration (months) of UP prior to azathioprine (IQR) | 20 (8–72) |
| Azathioprine started as monotherapy, n (%) | 19 (16) |
| Azathioprine started in combination with infliximab, n (%) | 3 (3) |
| Biologicals, n (%) | 33 (28) |
| Median duration (months) of UP prior to biologicals (IQR) | 76 (17–144) |
| Anti-TNF as first biological, n (%) | 25 (21) |
| Vedolizumab as first biological, n (%) | 8 (7) |
| Azathioprine as concomitant therapy with first biological, n (%) | 6 (5) |
| Appendectomy, n (%) | 4 (3) |
| Median duration (months) of UP at last follow-up (IQR) | 71 (29–149) |
5-ASA: 5-aminosalicylic acid; anti-TNF: anti-tumour necrosis factor; IQR: interquartile range; UC: ulcerative colitis; UP: ulcerative proctitis.